Top

Published in:

01-11-2009 | Case Report

Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia

Authors: Satoshi Horino, Takeshi Rikiishi, Hidetaka Niizuma, Hiroshi Abe, Yuko Watanabe, Masaei Onuma, Yoshiyuki Hoshi, Yoji Sasahara, Miyako Yoshinari, Takuro Kazama, Yutaka Hayashi, Satoru Kumaki, Shigeru Tsuchiya

Published in: International Journal of Hematology | Issue 4/2009

Abstract

Immune thrombocytopenic purpura (ITP) has been associated with several hematologic malignancies such as Hodgkin and non-Hodgkin lymphomas and chronic lymphocytic leukemia, but it is rare in children with acute lymphoblastic leukemia (ALL). Here, we report a 7-year-old girl with chronic ITP during early intensive phase of chemotherapy for ALL. She underwent splenectomy because thrombocytopenia had persisted even after treatment with intravenous immunoglobulin (IVIG), steroids, vincristine, rituximab, and anti-D antibody. After splenectomy, her platelet count had recovered, and maintenance therapy could be resumed with a support of IVIG. To our knowledge, this is the first child case of chronic ITP during chemotherapy for ALL and splenectomy was effective in this patient.

Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33:230–9.CrossRefPubMed

Martinelli G, Zinzani PL, Magagnoli M, et al. Incidence and prognostic significance of idiopathic thrombocytopenic purpura in patients with Hodgkin’s disease in complete hematological remission. Haematologica. 1998;83:669–70.PubMed

Rao S, Pang E. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. J Pediatr. 1979;94:408–9.CrossRefPubMed

Yenicesu I, Sanli C, Güegey A. Idiopathic thrombocytopenic purpura in acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2000;17:719–20.CrossRefPubMed

Kurekci AE, Atay AA, Demirkaya E, et al. Immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia and mumps. J Pediatr Hematol Oncol. 2006;28:170–2.CrossRefPubMed

Price V, Barnes C, Canning P, et al. Immune thrombocytopenia following successful treatment of cancer in children. Pediatr Blood Cancer. 2006;46:372–6.CrossRefPubMed

Campbell JK, Mitchell CA. Immune thrombocytopenia in association with acute lymphoblastic leukaemia and a haemophagocytic syndrome. Eur J Haematol. 1993;51:259–61.CrossRefPubMed

Kaushansky K. Thrombopoietin: a tool for understanding thrombopoiesis. J Thromb Haemost. 2003;1:1587–92.CrossRefPubMed

Saxon BR, Mody M, Blanchette VS, et al. Reticulated platelet counts in the diagnosis of acute immune thrombocytopenia purpura. J Pediatr Hematol Oncol. 1998;20:44–8.CrossRefPubMed

10.

Kuwana M, Okazaki Y, Satoh T, et al. Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005;118:1026–33.CrossRefPubMed

11.

Berchtold P, Müller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurements of anti-platelet autoantibodies. Br J Haematol. 1997;96:477–83.CrossRefPubMed

12.

Teachey DT, Felix CA. Development of cold agglutinin autoimmune hemolytic anemia during treatment for pediatric acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2005;27:397–9.CrossRefPubMed

13.

Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.CrossRefPubMed

14.

Liu B, Zhao H, Poon MC, et al. Abnormality of CD4⁺CD25⁺ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78:139–43.PubMed

15.

Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336–44.CrossRefPubMed

16.

Stevens W, Koene H, Zwaginga JJ, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med. 2006;64:356–63.PubMed

Title: Refractory chronic immune thrombocytopenic purpura in a child with acute lymphoblastic leukemia
Authors: Satoshi Horino
Takeshi Rikiishi
Hidetaka Niizuma
Hiroshi Abe
Yuko Watanabe
Masaei Onuma
Yoshiyuki Hoshi
Yoji Sasahara
Miyako Yoshinari
Takuro Kazama
Yutaka Hayashi
Satoru Kumaki
Shigeru Tsuchiya
Publication date: 01-11-2009
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2009
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-009-0424-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia

Phenotypic variations between affected siblings with ataxia-telangiectasia: ataxia-telangiectasia in Japan

Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome

Compound heterozygous mutations in the PROS1 gene responsible for quantitative and qualitative protein S deficiency

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

Keynote webinar | Spotlight on antibody–drug conjugates in cancer